The Manchester regional screening programme: a 10-year exercise in patient and family care

British Medical Journal
|September 15, 1979
PubMed

Insights

Newborn screening for metabolic disorders like phenylketonuria (PKU) is effective. Early detection and treatment of PKU significantly reduce healthcare costs compared to managing untreated cases.

Area of Science:

  • Biochemical Genetics
  • Public Health Screening

Background:

  • The Willink Biochemical Genetics Unit conducted extensive newborn screening.
  • Screening covered 98-99% of regional births over a decade.

Purpose of the Study:

  • To report on the outcomes of a decade of newborn screening for metabolic disorders.
  • To evaluate the cost-effectiveness of screening and treating phenylketonuria (PKU).

Main Methods:

  • Screening of 506,821 infants for metabolic abnormalities.
  • Detection and treatment of identified cases, including phenylketonuria (PKU), histidinaemia, and homocystinuria.
  • Cost analysis comparing screened and treated PKU cases versus untreated cases.

Main Results:

  • Detected 69 cases of phenylketonuria (PKU), 42 of histidinaemia, and 6 of homocystinuria.
  • Provided comprehensive family support and community liaison.
  • Screening and treating PKU in 1978 saved £569,000 compared to managing untreated patients.

Conclusions:

  • Newborn screening programs are vital for early detection of metabolic disorders.
  • Early intervention for conditions like PKU is more cost-effective than long-term care for untreated individuals.
  • Integrated community support enhances the effectiveness of genetic screening programs.